“This bill would require the Alabama Medicaid Agency to cover screening and would also regulate how Medicaid covers prescription drugs used to treat postpartum depression,” the legislation states.

Craske and her colleagues hypothesized that targeting this mechanism for reward sensitivity could help strengthen affected ...

Supernus Pharmaceuticals said on Tuesday its depression treatment trial failed to meet the main goal of reduction in depressive symptoms, sending its shares down 22% aftermarket.

Depression impacts overall health, accelerating the onset of chronic conditions by 30%. A study found that those with a ...

Major depressive disorder (MDD) is a leading cause of disability worldwide, with a significant proportion of patients (10-20%) progressing to treatment-resistant depression (TRD).

The company announced on 18 February that the trial did not meet its primary endpoint measured by a depression rating scale, ...

Supernus' SPN-820 Phase 2b study in treatment-resistant depression failed to meet its primary endpoint, prompting further ...

US CNS specialist Supernus Pharmaceuticals has announced that its Phase IIb study of SPN-820 in adults with ...

After SPN-820's failure, Supernus is relying on its non-stimulant ADHD drug Qelbree and the recently approved Parkinson’s ...

Depression doesn't just affect mood — it changes how people eat. Some lose their appetite, while others crave food, ...

Study did not demonstrate statistically significant improvement on primary endpoint of reduction in depressive symptoms as measured by MADRS total score compared to placeboSPN-820 was well-tolerated ...

New postpartum depression findings could lead to a blood test to identify women at risk and possibly even to a preventive treatment.